Evidence map›Paper›PMID 27789650›Full record

ArticleThorax2017

Time to share: lessons from post hoc analyses of IPF trials.

Daniel J Kass, Naftali Kaminski

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Daniel J KassDivision of Pulmonary, Allergy, and Critical Care Medicine, Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Naftali KaminskiSection of Pulmonary, Critical Care, and Sleep Medicine, Yale University, New Haven, Connecticut, USA.ORCID 0000-0001-5917-4601

Funding

Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Mir-29 mimicry as a therapy for pulmonary fibrosisUH3HL123886 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2016 to 2018
$4.5M
Mir-29 mimicry as a therapy for pulmonary fibrosisUH2HL123886 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2014 to 2015
$2.7M
Twist1 subphenotypes and pulmonary fibrosisR01HL126990 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KASS, DANIEL J · 2015 to 2019
$1.9M
NHLBI NIH HHS R01 HL126990NHLBI NIH HHS R01 HL127349NHLBI NIH HHS UH2 HL123886NHLBI NIH HHS UH3 HL123886
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Idiopathic Pulmonary FibrosisHumansIdiopathic pulmonary fibrosis

Identifiers

PMID27789650
PMCPMC5994758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.